Doxorubicin-vincristine therapy for Wilms' tumor: a pilot study. Cancer Treat Rep 1982 Oct;66(10):1791-4
Date
10/01/1982Pubmed ID
6290049Scopus ID
2-s2.0-0019931825 (requires institutional sign-in at Scopus site) 4 CitationsAbstract
Doxorubicin plus vincristine chemotherapy was given to 31 children following nephrectomy for Wilms' tumor. Radiation therapy was used as indicated. Disease-free survival by stage is: eight of nine patients (stage I), eight of nine (stage II), nine of ten (stage III), and two of three (stage IV). Median follow-up of survivors is 28 months (range, 2-67); for all but four patients, follow-up is greater than 12 months. Two of the three stage I-III failures occurred in children with unfavorable histologies; the third failure was due to fatal anthracycline cardiomyopathy. Lowering the maximal cumulative doxorubicin dose from 450 to 240 mg/m2 did not increase failures. Doxorubicin-vincristine appears to be effective chemotherapy for Wilms' tumor.
Author List
Camitta B, Kun L, Glicklich M, Oechler H, Adair S, Pinkel DAuthor
Bruce m. Camitta Professor in the Pediatrics department at Medical College of WisconsinMESH terms used to index this publication - Major topics in bold
AdolescentChild
Child, Preschool
Doxorubicin
Drug Evaluation
Drug Synergism
Drug Therapy, Combination
Female
Humans
Infant
Male
Nephrectomy
Vincristine
Wilms Tumor
